Scarica l'app Stockscreener
140.14
2.30%
3.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$136.99
Aprire:
$137.77
Volume 24 ore:
1.94M
Relative Volume:
1.10
Capitalizzazione di mercato:
$21.99B
Reddito:
$4.39B
Utile/perdita netta:
$-1.58B
Rapporto P/E:
-5.2664
EPS:
-26.61
Flusso di cassa netto:
$546.00M
1 W Prestazione:
+3.77%
1M Prestazione:
-2.72%
6M Prestazione:
+30.50%
1 anno Prestazione:
+43.35%
Intervallo 1D:
$136.05
$141.40
Intervallo di 1 settimana:
$129.15
$141.40
Portata 52W:
$93.51
$156.66
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Confronta ILMN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| ILMN | 140.14 | 21.99B | 4.39B | -1.58B | 546.00M | -26.61 |
| TMO | 513.26 | 196.64B | 42.37B | 6.14B | 7.78B | 15.26 |
| DHR | 235.84 | 170.44B | 23.74B | 3.89B | 4.98B | 7.93 |
| A | 133.84 | 38.48B | 6.50B | 1.41B | 1.42B | 3.82 |
| IQV | 201.82 | 36.63B | 15.32B | 1.41B | 1.96B | 5.95 |
| IDXX | 417.24 | 34.31B | 3.84B | 866.24M | 792.60M | 9.80 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Stocks With Rising Relative Strength: Illumina - MSN
Edgewood Management LLC Decreases Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Jennison Associates LLC Purchases 89,663 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Metagenomics Market Is Booming Worldwide 2024-2031 | Bio-Rad - openPR
United States Non-Invasive Prenatal Testing Market Report 2025-2033: Illumina, Roche, and Natera, which have Established Themselves as Leaders through Robust Research and Development - Yahoo Finance
Bioinformatics Market Size, Trends, Growth, Opportunities - openPR
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Trailblazing study shows early CGP leads to better precision treatments - Illumina
Connor Clark & Lunn Investment Management Ltd. Buys 114,466 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Myriad Genetics Announces Incorporation of its Proprietary - GlobeNewswire
Myriad Genetics Expands Illumina Partnership, Integrates Key Cancer Testing Technology | MYGN Stock News - StockTitan
(ILMN) Trading Report - Stock Traders Daily
Illumina's Moat in Sequencing Remains Narrow - Morningstar
Illumina gear up to expand TruSight Oncology portfolio - Yahoo Finance
ILMN Stock Set to Gain From Expansion of TruSight Oncology Portfolio - Yahoo Finance
Gene Panel Market: Rapid Growth with Strong Future CAGR and Top - openPR
Victory Capital Management Inc. Has $16.48 Million Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Biological Multiplex Assays Market to Witness Significant - openPR
U.S. STOCKS Merck, Microstrategy, Illumina - XM
Illumina to unveil new tumor profiling assay at AMP - Investing.com
Illumina announces expansion of TruSight Oncology portfolio - PR Newswire
LMR Partners LLP Acquires Shares of 21,285 Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
RNA Sequencing Market Expected to Experience Positive Growth - openPR
NGS Based RNA Sequencing Market 2024 Analysis of Key Trends, - openPR
Digital Genome Market May See a Big Move | Illumina, GE Healthcare, Inscripta - openPR
How two systems integration scientists ensure a smooth workflow on MiSeq i100 - Illumina
Is Illumina, Inc. (ILMN) the Best Immunotherapy Stock to Buy Now? - Yahoo Finance
Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Mutual of America Capital Management LLC - MarketBeat
CIBC Asset Management Inc Reduces Stock Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
10 Best Immunotherapy Stocks to Buy Now - Insider Monkey
NGS & Microarray Training - Illumina
Impax Asset Management Group plc Increases Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina Inc. stock underperforms Friday when compared to competitors - MarketWatch
North America Bioinformatics Market Statistical Forecast - openPR
ING Groep NV Raises Stake in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Plato Investment Management Ltd Raises Holdings in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Oppenheimer & Co. Inc. Sells 10,424 Shares of Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
DNA Test Kits Market Future Business Opportunities 2024-2031 | - openPR
Instrument Services - Illumina
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
12,000 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Freemont Management S.A. - MarketBeat
Entropy Technologies LP Invests $1.38 Million in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Illumina's SWOT analysis: ngs leader faces competition, aims for growth - Investing.com
Biochips Market Is Booming Worldwide 2024-2031 | Illumina, - openPR
Illumina's SWOT analysis: ngs leader faces competition, aims for growth By Investing.com - Investing.com UK
Urban Illumina 2024 at MDI Gurgaon Illuminates Insights, Entertainment, and Engagement through Disguised Market Research - Passionate In Marketing
Single-cell RNA analysis finds possible genetic drivers of bone cancer - Illumina
Mengis Capital Management Inc. Purchases New Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat
Consumer Genomics Industry Next Big Thing | Major Giants- Veritas, Illumina, Xcode Life - openPR
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.35%
1.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):